HRSA-23-066: Alliance for Innovation on Maternal Health (AIM) Capacity
Closed
This grant is closed. A newer notice from the same program is open now: Women's Initiative for Screening and Health (WISH) (HRSA-27-072). Status: Closes January 8, 2027 (62 days left). It is in our archive of Health Resources and Services Administration notices from 2023.
Health Resources and Services Administration offered grants to the applicants described in the notice. It expected to make about 29 awards worth $5.8 million in total. Applications closed on May 9, 2023.
From the official notice on Grants.gov, last changed March 10, 2023. Checked November 7, 2026.
- Total funding$5.8 million
- Expected awards29
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | March 10, 2023 |
|---|---|
| Deadline | May 9, 2023 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligible applicants include any domestic public or private entity. Domestic faith based and community-based organizations, tribes, and tribal organizations are also eligible to apply.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity to apply for funding under the Alliance for Innovation on Maternal Health (AIM) Capacity program. The AIM program is the national, cross-sector commitment designed to lead in the identification, development, implementation, and dissemination of maternal (patient) safety bundles for the promotion of safe care for every U.S. birth and assist with addressing the complex problem of high maternal mortality and SMM rates within the United States. The mission of AIM is to support best practices that make birth safer, improve the quality of maternal health care and outcomes, and save lives. Maternal safety bundles address topics commonly associated with health complications or risks related to prenatal, labor and delivery, and postpartum care. The AIM Capacity program is a new funding initiative designed to support state capacity to implement AIM and expand the reach, depth, and quality of AIM throughout the United States.1 These efforts are designed to meet the intent of the legislation which is “identifying, developing, or disseminating best practices to improve maternal health care quality and outcomes, improve maternal and infant health, and eliminate preventable maternal mortality and severe maternal morbidity”. To date, only seed funding has been provided to implement and support AIM at the state level. HRSA is increasing the resources available to states to provide greater support for increasing the number of states, hospitals, and other birthing facility settings implementing patient safety bundles; for increasing the number of bundles being implemented and/or sustained by birthing facilities; for supporting the fidelity of bundle delivery; and for promoting effective data collection and reporting. The AIM Capacity program will be one of two components of the AIM Program. The second component will be a cooperative agreement with HRSA for the HRSA-23-084 AIM Technical Assistance (TA) Center, which will provide TA to all 50 states, the District of Columbia (D.C.), jurisdictions, U.S. territories, tribal communities, and birthing facilities who are participating in the AIM program. The TA Center will also build data capacity for participating entities to track progress on bundle implementation and support improvement of data collection and reporting to measure program impact more effectively. For more details, see Program Requirements and Expectations.
Who has won Special Projects of Regional and National Significance grants before
From fiscal 2021 to 2025, Special Projects of Regional and National Significance (93.110) awarded $1.4 billion across 842 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Zero to Three National Center for Infants, Toddlers & Families | District of Columbia | 2 | $54.3 million |
| University Hospitals Cleveland Medical Center | Ohio | 1 | $51.5 million |
| Children's National Medical Center | District of Columbia | 1 | $37.2 million |
| University of North Carolina at Chapel Hill | North Carolina | 8 | $29.1 million |
| American Academy of Pediatrics | Illinois | 8 | $26.4 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HRSA-27-072, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-23-066 still open?
No. It closed on May 9, 2023. A newer notice is open: HRSA-27-072, closes January 8, 2027 (62 days left).
Who can apply for Alliance for Innovation on Maternal Health (AIM) Capacity?
Health Resources and Services Administration accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Alliance for Innovation on Maternal Health (AIM) Capacity?
Closed May 9, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $5.8 million in total across about 29 awards.
Who has won Special Projects of Regional and National Significance grants before?
The largest recipients over five fiscal years were Zero to Three National Center for Infants, Toddlers & Families, University Hospitals Cleveland Medical Center, Children's National Medical Center. The program made 842 awards worth $1.4 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)